Genfit (GNFT) has released an update.
GENFIT, a biopharmaceutical company focusing on liver diseases, reported a solid financial position with €77.8 million in cash and €28.6 million in revenue for the year 2023, boosted by a milestone payment of €13.3 million. The company highlighted significant progress in its drug development, including positive Phase 3 trial results for elafibranor in PBC and the advancement of its acute-on-chronic liver failure (ACLF) program with multiple assets. GENFIT anticipates key regulatory dates and trial data in 2024, aiming to address unmet medical needs in liver disease treatment.
For further insights into GNFT stock, check out TipRanks’ Stock Analysis page.
